Jafferji Mohammad S, Yang James C
Surgery Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, CRC Building 10, Room: 3-3832, Bethesda, MD 20892, USA.
Surgery Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, CRC Building 10, Room: 3-3832, Bethesda, MD 20892, USA.
Surg Oncol Clin N Am. 2019 Jul;28(3):465-479. doi: 10.1016/j.soc.2019.02.012. Epub 2019 Apr 12.
The use of immunotherapies for solid and hematologic malignancies has demonstrated durable antitumor effects. Use of checkpoint inhibitors allows for immunologic reactivation of the adaptive immune system against tumor-specific neoantigens and effective rejection. Recent developments in adoptive transfer of T cells has shown effective immune rejection of solid malignancies and durable regression. Adoptive cell transfer involves extraction of in vivo T lymphocytes, selection for or introduction of tumor reactive cells, in vitro expansion, and delivery of the T-cell product back to the patient. This article discusses the different approaches, challenges, and further directions of adoptive T-cell transfer in solid malignancies.
免疫疗法在实体瘤和血液系统恶性肿瘤中的应用已显示出持久的抗肿瘤效果。使用检查点抑制剂可使适应性免疫系统针对肿瘤特异性新抗原进行免疫重新激活并实现有效排斥。过继性T细胞转移的最新进展已显示出对实体瘤的有效免疫排斥和持久缓解。过继性细胞转移包括提取体内T淋巴细胞、选择或引入肿瘤反应性细胞、体外扩增，以及将T细胞产物回输至患者体内。本文讨论了实体瘤过继性T细胞转移的不同方法、挑战及未来方向。
